# Plasma-Cell Disorders: Myeloma, Waldenström Macroglobulinemia, and Related Monoclonal Gammopathies
**Lecturer:** David Iberri, M.D., Clinical Associate Professor of Medicine (Hematology)
**Date:** January 29, 2026

## Learning Objectives

### 1. Pathogenesis and Complications of Multiple Myeloma, Waldenström Macroglobulinemia, and Related Disorders
- Describe the development of clonal plasma-cell neoplasms from normal plasma cells
- Explain how monoclonal gammopathy develops
- Understand mechanisms by which B-cells/plasma-cells and their antibody products cause organ injury

### 2. Contrast Symptomatic Multiple Myeloma with Precursor Conditions and Related Disorders
- Distinguish MGUS from smoldering myeloma and active myeloma
- Compare multiple myeloma with Waldenström macroglobulinemia
- Understand the progression from precursor states to active disease

### 3. Interpret Diagnostic Studies Related to Monoclonal Gammopathy
- Understand protein electrophoresis (SPEP), immunofixation (IFE), and free light chain testing
- Identify monoclonal proteins and interpret test results
- Know when to screen for monoclonal gammopathy

### 4. Understand Principles of Myeloma and Waldenström Macroglobulinemia Therapy
- Describe the phases of myeloma treatment (induction, consolidation, maintenance)
- Understand the role of autologous stem-cell transplant
- Recognize available therapies and treatment goals

---

## Development of Clonal Plasma-Cell Neoplasms and Monoclonal Gammopathy

### Normal Plasma-Cell Function

**Plasma cells** produce antibodies (immunoglobulins) that consist of:
- **Heavy chains**: G, A, M, E, or D
- **Light chains**: Kappa (κ) or lambda (λ)
- **Intact antibody naming**: Each antibody is named by its heavy and light chain (e.g., IgGλ)

**Normal polyclonal state**:
- Multiple diverse plasma-cell clones exist
- Each produces a unique antibody
- Results in polyclonal antibodies in circulation

### Pathogenesis of Plasma-Cell Disorders

**Transformation process**:
- Over years of chronic antigen stimulation, plasma cells accumulate genetic changes
- A single clone may expand, leading to monoclonal plasma cells
- These clones produce identical antibodies, creating monoclonal gammopathy

**Key terminology**:
- **Plasma-cell neoplasm**: The clonal population of abnormal plasma cells
- **Monoclonal gammopathy**: The state of producing monoclonal antibodies
- These are two sides of the same coin

### Historical Context

Dr. Marian Elliott Koshland demonstrated in the 1950s that antibody specificity arises from differences in amino acid sequence, establishing the foundation for understanding monoclonal antibodies.

---

## Spectrum of Plasma-Cell Disorders

### MGUS (Monoclonal Gammopathy of Undetermined Significance)

**Definition**:
- Bone marrow involvement <10%
- Serum M-spike <3 g/dL
- No end-organ dysfunction related to the clonal neoplasm or monoclonal gammopathy

**Epidemiology**:
- Age-related prevalence increases with age
- Present in ~3.2% of people ≥50 years old
- 5.3% in those ≥70 years old
- 7.5% in those ≥85 years old
- More common in males than females

**Natural history**:
- Risk of progression to myeloma: ~1% per year
- Most MGUS remains indolent and does not progress
- All myeloma/Waldenström macroglobulinemia begins with MGUS
- Analogous to mole:melanoma or polyp:colon cancer relationship

### Smoldering Myeloma

**Definition**:
- Bone marrow involvement ≥10% OR serum M-spike ≥3 g/dL
- No end-organ dysfunction related to the clonal neoplasm or monoclonal gammopathy

**Risk of progression** (time-dependent):
- Years 1-5: 10% per year
- Years 5-10: 3% per year
- Years 10-20: 1% per year (similar to MGUS after 10 years)

### Active Multiple Myeloma

**Diagnostic criteria**:
- Bone marrow involvement >10%
- Any M-spike level
- **SLiM CRAB criteria** present:
  - **S**: ≥Sixty percent marrow involvement
  - **Li**: Light chain ratio ≥100
  - **M**: >1 focal lesion on MRI >5 mm
  - **C**: Hypercalcemia
  - **R**: Renal dysfunction
  - **A**: Anemia
  - **B**: Bone lesions

**Note**: SLiM criteria were added to traditional CRAB criteria to identify high-risk smoldering myeloma patients before they develop overt organ damage.

---

## Diagnostic Testing for Monoclonal Gammopathy

### Protein Electrophoresis

**Serum Protein Electrophoresis (SPEP)**:
- Separates proteins by size and charge
- Creates bands: albumin, alpha-1, alpha-2, beta, and gamma regions
- Immunoglobulins typically migrate in the gamma region
- Monoclonal proteins appear as a distinct "M-spike"
- Quantifies the amount of monoclonal protein

**Immunofixation Electrophoresis (IFE)**:
- Identifies the specific type of monoclonal protein
- Tests for IgG, IgA, IgM, kappa, and lambda
- Monoclonal proteins appear as narrow bands
- Polyclonal proteins appear as broad bands

### Free Light Chain Testing

**Purpose**:
- Detects excess free light chains in serum
- Some clones produce more light chains than heavy chains
- Some produce only light chains without intact immunoglobulin

**Interpretation**:
- Normal state: Kappa and lambda are roughly equal
- Monoclonal state: One light chain greatly exceeds the other
- Abnormal kappa/lambda ratio strongly suggests clonal process
- Complementary to SPEP/IFE, not more sensitive

### When to Screen for Monoclonal Gammopathy

**Screen when facing unexplained or incompletely explained**:
- Constitutional symptoms (fatigue, weight loss)
- CRAB signs/symptoms
- Heart, liver, or renal failure
- Neuropathy
- Skin findings

**Tests to order**:
- Serum IgG, IgA, IgM (serum IG panel)
- Serum protein electrophoresis and immunofixation (SPIE)
- Serum free light chains (FLCR)
- Urine protein electrophoresis and immunofixation (UPIE)

---

## Mechanisms of Organ Damage

### Cell-Mediated Damage

**Direct tumor effects**:
- Rapidly proliferating B-cells/plasma-cells in marrow, nodes, spleen (Waldenström macroglobulinemia)
- Plasma cells in marrow and bones (multiple myeloma)
- Plasma cells spilling into bloodstream (plasma-cell leukemia)
- Localized disease in marrow or soft tissue (solitary plasmacytoma)

### Paraprotein-Mediated Damage

**Autoantibody activity**:
- Binds red blood cells → autoimmune hemolysis (e.g., cold agglutinin disease)
- Binds platelets → secondary ITP
- Binds myelin → anti-MAG IgM neuropathy

**Concentration overwhelms**:
- Light chains → cast nephropathy ("myeloma kidney")
- IgM → Waldenström macroglobulinemia (hyperviscosity)

**Deposits in organs**:
- Just deposits → immunoglobulin deposition disease
- Misfolds, then deposits → light-chain amyloidosis (AL)
- Precipitates in cold, then deposits → Type 1 and 2 cryoglobulinemia

**Mysterious associations**:
- IgM, urticaria, fever → Schnitzler syndrome
- λ, neuropathy, ↑VEGF → POEMS syndrome

---

## Multiple Myeloma

### Overview

**Epidemiology**:
- About 35,000 new US cases annually (1% of all new cancer diagnoses)
- Median age at diagnosis: ~70 years

**Disease characteristics**:
- Disease of plasma cells and their antibody products
- Typically IgG, IgA, or light chain only disease (IgM rare)

**Major complications (CRAB)**:
- **C**: Hypercalcemia
- **R**: Renal failure (often from cast nephropathy)
- **A**: Anemia (from marrow replacement and chronic disease)
- **B**: Bone lesions (lytic lesions from osteoclast activation)

### Pathophysiology

**Bone disease mechanism**:
- Myeloma cells activate osteoclasts
- Suppress osteoblasts
- Results in lytic bone lesions and osteoporosis
- Leads to pathologic fractures and bone pain

**Renal injury**:
- Light chains filtered through glomerulus
- Mix with Tamm-Horsfall protein in tubules
- Form casts that obstruct tubules
- Causes acute tubular necrosis ("cast nephropathy")

**Expected survival**: >10-15 years in current era with modern therapies

---

## Waldenström Macroglobulinemia

### Overview

**Epidemiology**:
- About 1,500 cases annually in the US
- Median age ~70 years at diagnosis

**Disease characteristics**:
- Disease of B-cells and plasma cells (lymphoplasmacytic lymphoma)
- All patients have IgM paraprotein ("macro")
- MYD88 mutation in >90% of patients

### Major Complications

**Clinical features**:
- Anemia
- Splenomegaly
- Adenopathy
- Constitutional ("B") symptoms
- Neuropathy
- Hyperviscosity syndrome (from high IgM levels)
- Cryoglobulinemia

**Key differences from myeloma**:
- Usually absence of bone lesions
- Usually absence of renal failure
- Bone marrow involvement without bony destruction

### Hyperviscosity Syndrome

**Mechanism**: Large pentameric IgM molecules increase serum viscosity

**Clinical manifestations**:
- Headache and visual changes
- Bleeding (retinal hemorrhages, epistaxis)
- Neurologic symptoms

**Prognosis**: Measured in years to decades (prevalence >> incidence)

---

## Framework for Understanding B-Cell/Plasma-Cell Disorders

### Conceptual Model

Disorders can be categorized by:
- **Tumor-related damage**: From the cells themselves (NHL, MM, WM)
- **Paraprotein-related damage**: From the antibodies produced (MGCS - monoclonal gammopathy of clinical significance)
- **Both tumor and paraprotein damage**: Overlap conditions

**MGCS (Monoclonal Gammopathy of Clinical Significance)**:
- Monoclonal gammopathy causing organ damage
- But not meeting criteria for myeloma or lymphoma
- Examples: AL amyloidosis, POEMS syndrome, Schnitzler syndrome

---

## Principles of Myeloma Therapy

### Treatment Goals

**Current state**:
- Myeloma is considered incurable with conventional therapy
- However, we may be on the cusp of cure with immunotherapies
- Treatment focuses on inducing and maintaining remissions
- Expected survival >10-15 years with modern therapies

### Phases of Initial Therapy

**1. Induction chemotherapy**:
- Goal: Induce a remission
- Uses moderate-intensity combination chemotherapy
- Common regimens include combinations of:
  - Steroids (dexamethasone)
  - Immunomodulators (lenalidomide, pomalidomide)
  - Proteasome inhibitors (bortezomib, carfilzomib)
  - Monoclonal antibodies (daratumumab, isatuximab)

**2. Consolidation**:
- Goal: Deepen the remission
- Typically involves autologous hematopoietic stem-cell transplant
- Process:
  1. Collect patient's own stem cells from blood or marrow
  2. Process and concentrate stem cells
  3. Cryopreserve stem cells
  4. Administer high-dose chemotherapy (myeloablative, typically melphalan)
  5. Reinfuse thawed stem cells to rescue bone marrow
- High-dose chemotherapy is effective against myeloma but toxic to marrow
- Autotransplant allows safe administration of high-dose therapy

**3. Maintenance therapy**:
- Goal: Maintain remission as long as possible
- Uses low-intensity continuous therapy
- Commonly lenalidomide or other agents

### Relapsed/Refractory Disease

**Natural history**:
- Disease invariably relapses after initial control
- Cycles of remission and relapse continue
- Remission duration typically shortens with each relapse
- Multiple effective therapies available for relapsed disease

### Available Drug Classes

**Evolution of therapies**:
- **1960s**: Melphalan + prednisone
- **1990s**: Transplant, thalidomide, bisphosphonates
- **2000s**: Bortezomib, lenalidomide, carfilzomib, pomalidomide
- **2010s**: Daratumumab, elotuzumab, ixazomib, panobinostat, maintenance
- **2020s**: Isatuximab, selinexor, belantamab, CAR-T (ide-cel, cilta-cel), teclistamab, talquetamab, elranatamab, linvoseltamab

**Major drug classes**:
- Alkylating agents (cyclophosphamide, melphalan)
- Corticosteroids (dexamethasone)
- Proteasome inhibitors (bortezomib, carfilzomib, ixazomib)
- Immunomodulators (lenalidomide, pomalidomide, thalidomide)
- Monoclonal antibodies (daratumumab, isatuximab, elotuzumab)
- T-cell redirection therapy (CAR-T, bispecific antibodies)

### CAR T-Cell Therapy

**Mechanism**:
1. Patient's leukocytes collected by apheresis
2. T-cells activated and transduced with CAR (chimeric antigen receptor)
3. CAR directs T-cells to recognize myeloma cells (typically anti-BCMA)
4. T-cells proliferate ex vivo
5. Patient receives lymphocyte-depleting chemotherapy
6. CAR T-cells infused back into patient

**Clinical use**:
- Highly effective in relapsed/refractory myeloma
- FDA-approved CAR-T products: ciltacabtagene (Carvykti), idecabtagene (Abecma)

### Treatment Costs

**Annual costs of common regimens**:
- Rd (lenalidomide + dexamethasone): $168,000
- VRd (bortezomib + lenalidomide + dexamethasone): $200,000
- KRd (carfilzomib + lenalidomide + dexamethasone): $300,000
- D-Rd (daratumumab + lenalidomide + dexamethasone): $290,000
- D-VRd: $340,000
- D-KRd: $420,000
- Carvykti (CAR-T): $465,000 (one-time cost)
- Teclistamab: $475,000 annually

**Note**: Lenalidomide (Revlimid) costs have increased dramatically from $293/capsule in 2009 to $598/capsule in 2018.

---

## Principles of Waldenström Macroglobulinemia Therapy

### Treatment Approach

**When to treat**: Symptomatic disease requiring intervention

**Available therapies**:
- Alkylating agents (cyclophosphamide, bendamustine)
- Anti-CD20 monoclonal antibodies (rituximab)
- BTK inhibitors (ibrutinib, zanubrutinib) - particularly effective given MYD88 mutation
- Proteasome inhibitors (bortezomib)

**Key difference from myeloma**: Autologous transplant not standard of care for WM

---

## Key Concepts Summary

### Pathogenesis
- Normal plasma cells can transform into clonal neoplasms over years of antigen stimulation
- Monoclonal gammopathy results from single clone producing identical antibodies
- Both cells and antibodies can cause organ damage

### Disease Spectrum
- MGUS → Smoldering myeloma → Active myeloma represents continuum
- Risk of progression increases with higher disease burden
- All myeloma begins with MGUS, but most MGUS remains stable

### Diagnosis
- SPEP identifies and quantifies monoclonal proteins
- IFE determines the specific immunoglobulin type
- Free light chain testing complements SPEP/IFE
- Screen for monoclonal gammopathy with unexplained organ dysfunction

### Myeloma vs. Waldenström
- Myeloma: plasma cells, IgG/IgA/light chain, bone lesions, renal failure
- WM: lymphoplasmacytic cells, IgM, adenopathy, hyperviscosity, usually no bone lesions

### Treatment
- Myeloma therapy occurs in phases: induction, consolidation, maintenance
- Modern therapies have dramatically improved survival (>10-15 years)
- Treatment is costly but effective
- Cure may be achievable with immunotherapies

---

## Clinical Pearls

1. Consider monoclonal gammopathy screening for unexplained constitutional symptoms, CRAB features, neuropathy, or organ dysfunction

2. MGUS is common (3-7% of older adults) but progression risk is low (~1% per year)

3. Free light chain testing is complementary to, not a replacement for, SPEP/IFE

4. SLiM CRAB criteria identify high-risk patients before irreversible organ damage occurs

5. Myeloma causes bone lesions and renal failure; WM typically does not

6. Modern myeloma therapy has transformed the disease from rapidly fatal to chronic with >10-year survival

7. CAR-T therapy and bispecific antibodies represent major advances in myeloma treatment

8. Despite advances, myeloma remains incurable, but cure may be achievable in the near future

---

## File Location
**Lecture PDF**: `/Users/rpark23/Desktop/current/med-school/q5/som/heme/lectures/INDE-223B-01-29-2026-11-lect-David_Iberri-1.pdf`

**Summary**: `/Users/rpark23/Desktop/current/med-school/q5/som/heme/learning-objectives/INDE-223B-01-29-2026-11-lect-David_Iberri-1-summary.md`
